Close
GS1 Global Healthcare Conference 2026
LiGHT 2026

SIFI and Bausch Health Russia Announce Strategic Commercial Partnership

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

How to Know If You Need...

Tooth pain is one of those things that's easy...

GE HealthCare Secures CE Mark for...

GE HealthCare has secured CE Mark certification for its...

Revvity Launches GSP T1D 3plex Kit...

Revvity has launched the GSP T1D 3plex kit, a...

SIFI, a leading international ophthalmic company, announces it has entered into a strategic multi-year agreement with Bausch Health Russia to market its innovative products treating ophthalmic disorders in Russia.

Initial sales are expected in 2021, marketing 5 SIFI products, segments of a comprehensive and established ophthalmic portfolio. These include:

  • COLBIOCIN™, NETTAVISC™ and NETTACIN™, antibiotic solutions indicated for the treatment of external eye infections and available in multiple dosage forms;
  • OCTILIA™, an eye-drop solution indicated for the treatment of irritations, reddening, ocular congestion and itching due to allergic, chemical or physical causes;
  • MIRTILENE FORTE CAPSULES, a retinotrophic vasoprotective food supplement, helpful in cases of capillary fragility or vascular alterations due to diabetic retinopathy.

Bausch Health Russia will have the option to commercialize future SIFI products currently under development.

“SIFI is committed to continuous development and expansion and is pleased to announce this strategic partnership with Bausch Health Russia,” said Gilberto Dalesio, SIFI’s CCO. “By joining forces SIFI will strengthen its global footprint and establish its presence in Russia, one of the fastest growing pharmaceutical markets in the world, and will enable Russian eye care doctors to address a wide variety of ophthalmic disorders, delivering significant benefits to Russian patients.”

“Bausch Health is pleased to partner with SIFI, because together we can ensure Russian eye health doctors and their patients have greater access to these important ophthalmic medications,” said Cees Heiman, Vice President Europe/Russia Pharmaceuticals, Bausch Health.

About SIFI

SIFI is a leading ophthalmic company, headquartered in Italy, focusing on eye care since 1935. SIFI develops, manufactures and markets innovative therapeutic solutions for patients with ophthalmic diseases. SIFI is committed to improve patients’ quality of life through its R&D efforts, exporting products to more than 20 countries worldwide with commercial operations in Italy, Spain, France, Romania, Mexico and Turkey.

Never miss a healthcare headline

Healthcare moves fast – stay on top of it with our must - read briefings.

  • The top hospital and healthcare stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments transforming global healthcare management

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

How to Know If You Need a Root Canal

Tooth pain is one of those things that's easy...

The Cigna Group Partners with OpenAI to Enhance Oncology Care Workflows

The Cigna Group has entered into a strategic partnership...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »